{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:43:38Z","timestamp":1786121018350,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05346-w","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:15:27Z","timestamp":1780510527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the effects of olanzapine on appetite and weight in patients with cancer in a systematic review"],"prefix":"10.1007","volume":"17","author":[{"given":"Marie Charlotte","family":"Renaux Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam\u00e9lia","family":"Smati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Noujaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Brugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoubir","family":"Djerada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Coutureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Slimano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"5346_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/CMAR.S417238","volume":"15","author":"S Takahashi","year":"2023","unstructured":"Takahashi S, Matsumoto K, Ohba K, Nakano Y, Miyazawa Y, Kawaguchi T. The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancer Manag Res. 2023;15:1033\u201346. https:\/\/doi.org\/10.2147\/CMAR.S417238.","journal-title":"Cancer Manag Res"},{"key":"5346_CR2","unstructured":"Joly F, Anota A, Foucaut A-M, V\u00e9die A-L, Antoun S, Barnoud D et al. Recommandations communes avec la SFNCM et l\u2019AFSOS n.d."},{"key":"5346_CR3","doi-asserted-by":"publisher","first-page":"175883591989985","DOI":"10.1177\/1758835919899852","volume":"12","author":"R Caccialanza","year":"2020","unstructured":"Caccialanza R, Goldwasser F, Marschal O, Ottery F, Schiefke I, Tilleul P, et al. Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. Ther Adv Med Oncol. 2020;12:1758835919899852. https:\/\/doi.org\/10.1177\/1758835919899852.","journal-title":"Ther Adv Med Oncol"},{"key":"5346_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"key":"5346_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ctrv.2008.03.003","volume":"34","author":"P Senesse","year":"2008","unstructured":"Senesse P, Assenat E, Schneider S, Chargari C, Magn\u00e9 N, Azria D, et al. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev. 2008;34:568\u201375. https:\/\/doi.org\/10.1016\/j.ctrv.2008.03.003.","journal-title":"Cancer Treat Rev"},{"key":"5346_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","volume":"186","author":"M Ferrer","year":"2023","unstructured":"Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ, et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023;186:1824\u201345. https:\/\/doi.org\/10.1016\/j.cell.2023.03.028.","journal-title":"Cell"},{"key":"5346_CR7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.clnu.2017.01.007","volume":"37","author":"A Jouinot","year":"2018","unstructured":"Jouinot A, Vazeille C, Durand JP, Huillard O, Boudou-Rouquette P, Coriat R, et al. Resting energy expenditure in the risk assessment of anticancer treatments. Clin Nutr Edinb Scotl. 2018;37:558\u201365. https:\/\/doi.org\/10.1016\/j.clnu.2017.01.007.","journal-title":"Clin Nutr Edinb Scotl"},{"key":"5346_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2016.05.032","volume":"64","author":"C Gavazzi","year":"2016","unstructured":"Gavazzi C, Colatruglio S, Valoriani F, Mazzaferro V, Sabbatini A, Biffi R, et al. Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. Eur J Cancer Oxf Engl 1990. 2016;64:107\u201312. https:\/\/doi.org\/10.1016\/j.ejca.2016.05.032.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"5346_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.radonc.2017.10.015","volume":"126","author":"E Cereda","year":"2018","unstructured":"Cereda E, Cappello S, Colombo S, Klersy C, Imarisio I, Turri A, et al. Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018;126:81\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2017.10.015.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5346_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.2015.61.6441","volume":"34","author":"LA Renfro","year":"2016","unstructured":"Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll H-J, et al. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:144\u201350. https:\/\/doi.org\/10.1200\/JCO.2015.61.6441.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5346_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/1055-9965.EPI-17-0200","volume":"26","author":"BJ Caan","year":"2017","unstructured":"Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2017;26:1008\u201315. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0200.","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"5346_CR12","doi-asserted-by":"publisher","first-page":"e172319","DOI":"10.1001\/jamaoncol.2017.2319","volume":"3","author":"EMC Feliciano","year":"2017","unstructured":"Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncol. 2017;3:e172319. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2319.","journal-title":"JAMA Oncol"},{"key":"5346_CR13","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00520-019-04767-4","volume":"27","author":"H Hua","year":"2019","unstructured":"Hua H, Xu X, Tang Y, Ren Z, Xu Q, Chen L. Effect of sarcopenia on clinical outcomes following digestive carcinoma surgery: a meta-analysis. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2019;27:2385\u201394. https:\/\/doi.org\/10.1007\/s00520-019-04767-4.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"5346_CR14","doi-asserted-by":"publisher","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","volume":"7","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Blanchet B, Durand J-P, Boudou-Rouquette P, Michels J, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE. 2012;7:e37563. https:\/\/doi.org\/10.1371\/journal.pone.0037563.","journal-title":"PLoS ONE"},{"key":"5346_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejca.2016.05.011","volume":"63","author":"KA Klute","year":"2016","unstructured":"Klute KA, Brouwer J, Jhawer M, Sachs H, Gangadin A, Ocean A, et al. Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. Eur J Cancer Oxf Engl 1990. 2016;63:189\u2013200. https:\/\/doi.org\/10.1016\/j.ejca.2016.05.011.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"5346_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1079\/BJN20041152","volume":"92","author":"SM Schneider","year":"2004","unstructured":"Schneider SM, Veyres P, Pivot X, Soummer A-M, Jambou P, Filippi J, et al. Malnutrition is an independent factor associated with nosocomial infections. Br J Nutr. 2004;92:105\u201311. https:\/\/doi.org\/10.1079\/BJN20041152.","journal-title":"Br J Nutr"},{"key":"5346_CR17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/sj.bjc.6605578","volume":"102","author":"M Pressoir","year":"2010","unstructured":"Pressoir M, Desn\u00e9 S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966\u201371. https:\/\/doi.org\/10.1038\/sj.bjc.6605578.","journal-title":"Br J Cancer"},{"key":"5346_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2018.12.003","volume":"196","author":"M Hilmi","year":"2019","unstructured":"Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, et al. Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135\u201359. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.12.003.","journal-title":"Pharmacol Ther"},{"key":"5346_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1475-2891-11-27","volume":"11","author":"CG Lis","year":"2012","unstructured":"Lis CG, Gupta D, Lammersfeld CA, Markman M, Vashi PG. Role of nutritional status in predicting quality of life outcomes in cancer\u2013a systematic review of the epidemiological literature. Nutr J. 2012;11:27. https:\/\/doi.org\/10.1186\/1475-2891-11-27.","journal-title":"Nutr J"},{"key":"5346_CR20","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3390\/nu7042145","volume":"7","author":"N-C Gellrich","year":"2015","unstructured":"Gellrich N-C, Handschel J, Holtmann H, Kr\u00fcskemper G. Oral cancer malnutrition impacts weight and quality of life. Nutrients. 2015;7:2145\u201360. https:\/\/doi.org\/10.3390\/nu7042145.","journal-title":"Nutrients"},{"key":"5346_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00520-020-05496-9","volume":"29","author":"E \u00c1lvaro Sanz","year":"2021","unstructured":"\u00c1lvaro Sanz E, Abil\u00e9s J, Garrido Siles M, P\u00e9rez Ru\u00edz E, Alcaide Garc\u00eda J, Rueda Dom\u00ednguez A. Impact of weight loss on cancer patients\u2019 quality of life at the beginning of the chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2021;29:627\u201334. https:\/\/doi.org\/10.1007\/s00520-020-05496-9.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"5346_CR22","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.23.01280","volume":"41","author":"EJ Roeland","year":"2023","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Smith TJ, Loprinzi CL. Cancer Cachexia Expert Panel. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:4178\u20139. https:\/\/doi.org\/10.1200\/JCO.23.01280.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5346_CR23","doi-asserted-by":"publisher","first-page":"100092","DOI":"10.1016\/j.esmoop.2021.100092","volume":"6","author":"J Arends","year":"2021","unstructured":"Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines\u2606. ESMO Open. 2021;6:100092. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100092.","journal-title":"ESMO Open"},{"key":"5346_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"key":"5346_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1176\/appi.focus.18306","volume":"18","author":"M Huhn","year":"2020","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. Focus Am Psychiatr Publ. 2020;18:443\u201355. https:\/\/doi.org\/10.1176\/appi.focus.18306.","journal-title":"Focus Am Psychiatr Publ"},{"key":"5346_CR26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"5346_CR27","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. https:\/\/doi.org\/10.1136\/bmj.l6890.","journal-title":"BMJ"},{"key":"5346_CR28","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"5346_CR29","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"5346_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M, et al. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast Edinb Scotl. 2020;50:30\u20138. https:\/\/doi.org\/10.1016\/j.breast.2020.01.005.","journal-title":"Breast Edinb Scotl"},{"key":"5346_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","volume":"54","author":"M Clemons","year":"2020","unstructured":"Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, et al. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. Breast Edinb Scotl. 2020;54:278\u201385. https:\/\/doi.org\/10.1016\/j.breast.2020.11.002.","journal-title":"Breast Edinb Scotl"},{"key":"5346_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s10147-019-01570-3","volume":"25","author":"V Vimolchalao","year":"2020","unstructured":"Vimolchalao V, Sakdejayont S, Wongchanapai P, Sukprakun S, Angspatt P, Thawinwisan W, et al. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Int J Clin Oncol. 2020;25:396\u2013402. https:\/\/doi.org\/10.1007\/s10147-019-01570-3.","journal-title":"Int J Clin Oncol"},{"key":"5346_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/1735-1995.192504","volume":"21","author":"N Nikbakhsh","year":"2016","unstructured":"Nikbakhsh N, Sadeghi MV, Ramzani E, Moudi S, Bijani A, Yousefi R, et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. J Res Med Sci Off J Isfahan Univ Med Sci. 2016;21:88. https:\/\/doi.org\/10.4103\/1735-1995.192504.","journal-title":"J Res Med Sci Off J Isfahan Univ Med Sci"},{"key":"5346_CR34","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2174\/1381612829666230804114538","volume":"29","author":"Y An","year":"2023","unstructured":"An Y, Zhang Z, Gu M, Zhao J, Jiang C, Zhao L, et al. Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial. Curr Pharm Des. 2023;29:1867\u201374. https:\/\/doi.org\/10.2174\/1381612829666230804114538.","journal-title":"Curr Pharm Des"},{"key":"5346_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014;47:542\u201350. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.05.003.","journal-title":"J Pain Symptom Manage"},{"key":"5346_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, et al. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and\/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020;6:895\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1052.","journal-title":"JAMA Oncol"},{"key":"5346_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/ecc.12260","volume":"24","author":"J Liu","year":"2015","unstructured":"Liu J, Tan L, Zhang H, Li H, Liu X, Yan Z, et al. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl). 2015;24:436\u201343. https:\/\/doi.org\/10.1111\/ecc.12260.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"5346_CR38","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, et al. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:2617\u201327. https:\/\/doi.org\/10.1200\/JCO.22.01997.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5346_CR39","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00520-009-0739-7","volume":"18","author":"RM Navari","year":"2010","unstructured":"Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2010;18:951\u20136. https:\/\/doi.org\/10.1007\/s00520-009-0739-7.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"5346_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.22037\/ijpr.2020.113955.14584","volume":"19","author":"A Maleki","year":"2020","unstructured":"Maleki A, Ghadiyani M, Salamzadeh J, Salari S, Banihashem S, Tavakoli-Ardakani M. Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer. Iran J Pharm Res IJPR. 2020;19:451\u201364. https:\/\/doi.org\/10.22037\/ijpr.2020.113955.14584.","journal-title":"Iran J Pharm Res IJPR"},{"key":"5346_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00432-024-05712-7","volume":"150","author":"J Shen","year":"2024","unstructured":"Shen J, Zhao J, Jin G, Li H, Jiang Y, Wu Y, et al. A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy. J Cancer Res Clin Oncol. 2024;150:283. https:\/\/doi.org\/10.1007\/s00432-024-05712-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5346_CR42","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1007\/s00520-020-05380-6","volume":"28","author":"S Ithimakin","year":"2020","unstructured":"Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 2020;28:5335\u201342. https:\/\/doi.org\/10.1007\/s00520-020-05380-6.","journal-title":"Support Care Cancer"},{"key":"5346_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.24287\/1726-1708-2022-21-4-70-82","volume":"21","author":"\u041d\u0412 \u0416\u0443\u043a\u043e\u0432","year":"2022","unstructured":"\u0416\u0443\u043a\u043e\u0432 \u041d\u0412, \u0420\u0430\u0431\u0430\u0435\u0432\u0430 \u041b\u041b, \u041b\u0438\u0442\u0432\u0438\u043d\u043e\u0432 \u0414\u0412. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0438 \u0431\u0435\u0437\u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u044c \u043c\u0430\u043b\u044b\u0445 \u0434\u043e\u0437 \u043e\u043b\u0430\u043d\u0437\u0430\u043f\u0438\u043d\u0430 \u0432 \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0435 \u0442\u043e\u0448\u043d\u043e\u0442\u044b \u0438 \u0440\u0432\u043e\u0442\u044b \u0443 \u0434\u0435\u0442\u0435\u0439 \u0438 \u043f\u043e\u0434\u0440\u043e\u0441\u0442\u043a\u043e\u0432, \u043f\u043e\u043b\u0443\u0447\u0430\u044e\u0449\u0438\u0445 \u0432\u044b\u0441\u043e\u043a\u043e\u044d\u043c\u0435\u0442\u043e\u0433\u0435\u043d\u043d\u0443\u044e \u0445\u0438\u043c\u0438\u043e\u0442\u0435\u0440\u0430\u043f\u0438\u044e. \u041f\u0440\u043e\u043c\u0435\u0436\u0443\u0442\u043e\u0447\u043d\u044b\u0435 \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0440\u0430\u043d\u0434\u043e\u043c\u0438\u0437\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u0433\u043e \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f. \u0412\u043e\u043f\u0440\u043e\u0441\u044b \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0438 \u0418 \u0418\u043c\u043c\u0443\u043d\u043e\u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438. \u0412 \u041f\u0435\u0434\u0438\u0430\u0442\u0440\u0438\u0438. 2022;21:70\u201382. https:\/\/doi.org\/10.24287\/1726-1708-2022-21-4-70-82.","journal-title":"\u0412 \u041f\u0435\u0434\u0438\u0430\u0442\u0440\u0438\u0438"},{"key":"5346_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12032-017-1074-3","volume":"35","author":"N Mehra","year":"2017","unstructured":"Mehra N, Ganesan P, Ganesan TS, Veeriah S, Boopathy A, Radhakrishnan V, et al. Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy. Med Oncol Northwood Lond Engl. 2017;35:12. https:\/\/doi.org\/10.1007\/s12032-017-1074-3.","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"5346_CR45","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2147\/CMAR.S280995","volume":"13","author":"M Suehiro","year":"2021","unstructured":"Suehiro M, Kojima Y, Takahashi M, Ito Y, Keira T, Ikegawa K, et al. Antiemetic Efficacy of Adding Olanzapine 5\u00a0mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide. Cancer Manag Res. 2021;13:1617\u201324. https:\/\/doi.org\/10.2147\/CMAR.S280995.","journal-title":"Cancer Manag Res"},{"key":"5346_CR46","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.2147\/CMAR.S191330","volume":"11","author":"H Okamoto","year":"2019","unstructured":"Okamoto H, Shono K, Nozaki-Taguchi N. Low-dose of olanzapine has ameliorating effects on cancer-related anorexia. Cancer Manag Res. 2019;11:2233\u20139. https:\/\/doi.org\/10.2147\/CMAR.S191330.","journal-title":"Cancer Manag Res"},{"key":"5346_CR47","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.2147\/CMAR.S254398","volume":"12","author":"X Wu","year":"2020","unstructured":"Wu X, Wu J, Tong G, Cheng B, Chen M, Yu S, et al. Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. Cancer Manag Res. 2020;12:6575\u201383. https:\/\/doi.org\/10.2147\/CMAR.S254398.","journal-title":"Cancer Manag Res"},{"key":"5346_CR48","unstructured":"European Medicines Agency (EMA). (n.d.). Zyprexa: EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zyprexa-epar-product-information_en.pdf. n.d"},{"key":"5346_CR49","doi-asserted-by":"publisher","first-page":"8235","DOI":"10.3390\/curroncol29110650","volume":"29","author":"X-L Zhang","year":"2022","unstructured":"Zhang X-L, Ying J-E. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug. Curr Oncol Tor Ont. 2022;29:8235\u201343. https:\/\/doi.org\/10.3390\/curroncol29110650.","journal-title":"Curr Oncol Tor Ont"},{"key":"5346_CR50","volume-title":"LiverTox Clin. Res. Inf. Drug-Induc. Liver Inj","author":"Olanzapine","year":"2012","unstructured":"Olanzapine. LiverTox Clin. Res. Inf. Drug-Induc. Liver Inj. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"5346_CR51","doi-asserted-by":"publisher","first-page":"114885","DOI":"10.1016\/j.bbr.2024.114885","volume":"463","author":"X Liu","year":"2024","unstructured":"Liu X, Lan X, Zhang X, Ye H, Shen L, Hu M, et al. Olanzapine attenuates 5-HT2cR and GHSR1a interaction to increase orexigenic hypothalamic NPY: Implications for neuronal molecular mechanism of metabolic side effects of antipsychotics. Behav Brain Res. 2024;463:114885. https:\/\/doi.org\/10.1016\/j.bbr.2024.114885.","journal-title":"Behav Brain Res"},{"key":"5346_CR52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/MPA.0000000000000335","volume":"44","author":"T Miura","year":"2015","unstructured":"Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, et al. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas. 2015;44:756\u201363. https:\/\/doi.org\/10.1097\/MPA.0000000000000335.","journal-title":"Pancreas"},{"key":"5346_CR53","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1113\/jphysiol.2014.284240","volume":"593","author":"AD Farmer","year":"2015","unstructured":"Farmer AD, Ban VF, Coen SJ, Sanger GJ, Barker GJ, Gresty MA, et al. Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. J Physiol. 2015;593:1183\u201396. https:\/\/doi.org\/10.1113\/jphysiol.2014.284240.","journal-title":"J Physiol"},{"key":"5346_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(15)00558-6.","journal-title":"Lancet Oncol"},{"key":"5346_CR55","doi-asserted-by":"publisher","first-page":"104594","DOI":"10.1016\/j.psyneuen.2020.104594","volume":"114","author":"X Chen","year":"2020","unstructured":"Chen X, Yu Y, Zheng P, Jin T, He M, Zheng M, et al. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice. Psychoneuroendocrinology. 2020;114:104594. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.104594.","journal-title":"Psychoneuroendocrinology"},{"key":"5346_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2003;28:519\u201326. https:\/\/doi.org\/10.1038\/sj.npp.1300027.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"5346_CR57","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.psyneuen.2017.08.022","volume":"85","author":"M He","year":"2017","unstructured":"He M, Zhang Q, Deng C, Jin T, Song X, Wang H, et al. Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity. Psychoneuroendocrinology. 2017;85:190\u20139. https:\/\/doi.org\/10.1016\/j.psyneuen.2017.08.022.","journal-title":"Psychoneuroendocrinology"},{"key":"5346_CR58","unstructured":"F\u00e9d\u00e9ration Fran\u00e7aise de Nutrition. (FFN) Reco368_recommandations_denutrition_pa_cd_20211110_v1.pdf. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-11\/reco368_recommandations_denutrition_pa_cd_20211110_v1.pdf n. d. Accessed 29 Dec 2024."},{"key":"5346_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12603-019-1176-z","volume":"23","author":"E Dent","year":"2019","unstructured":"Dent E, Hoogendijk EO, Visvanathan R, Wright ORL. Malnutrition Screening and Assessment in Hospitalised Older People: a Review. J Nutr Health Aging. 2019;23:431\u201341. https:\/\/doi.org\/10.1007\/s12603-019-1176-z.","journal-title":"J Nutr Health Aging"},{"key":"5346_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","volume":"38","author":"T Cederholm","year":"2019","unstructured":"Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr Edinb Scotl. 2019;38:1\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2018.08.002.","journal-title":"Clin Nutr Edinb Scotl"},{"key":"5346_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00228-024-03770-x","volume":"81","author":"L Yuan","year":"2025","unstructured":"Yuan L, Li X-Y, Xu L, Quan S-J, Huang Y-B, Zheng H. Effects of olanzapine in the improvement of body weight and appetite in patients with cancer or receiving chemotherapy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2025;81:45\u201363. https:\/\/doi.org\/10.1007\/s00228-024-03770-x.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05346-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:21:31Z","timestamp":1786069291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05346-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5346"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05346-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1133"}}